572 related articles for article (PubMed ID: 22788845)
1. Comparative in vitro antifungal susceptibility activity of amphotericin B versus amphotericin B methyl ester against Candida albicans ocular isolates.
Thanathanee O; Miller D; Ringel DM; Schaffner CP; Alfonso EC; O'Brien TP
J Ocul Pharmacol Ther; 2012 Dec; 28(6):589-92. PubMed ID: 22788845
[TBL] [Abstract][Full Text] [Related]
2. Comparative antifungal susceptibility analysis of Candida albicans versus non-albicans Candida corneal isolates.
Spierer O; Dugar J; Miller D; OʼBrien TP
Cornea; 2015 May; 34(5):576-9. PubMed ID: 25826327
[TBL] [Abstract][Full Text] [Related]
3. Comparative susceptibility of Candida albicans to amphotericin B and amphotericin B methyl ester.
Bannatyne RM; Cheung R
Antimicrob Agents Chemother; 1977 Oct; 12(4):449-50. PubMed ID: 335958
[TBL] [Abstract][Full Text] [Related]
4. Comparison of antifungal efficacies of moxifloxacin, liposomal amphotericin B, and combination treatment in experimental Candida albicans endophthalmitis in rabbits.
Deren YT; Ozdek S; Kalkanci A; Akyürek N; Hasanreisoğlu B
Can J Microbiol; 2010 Jan; 56(1):1-7. PubMed ID: 20130687
[TBL] [Abstract][Full Text] [Related]
5. Comparative in vitro and in vivo evaluation of N-D-ornithyl amphotericin B methyl ester, amphotericin B methyl ester, and amphotericin B.
Parmegiani RM; Loebenberg D; Antonacci B; Yarosh-Tomaine T; Scupp R; Wright JJ; Chiu PJ; Miller GH
Antimicrob Agents Chemother; 1987 Nov; 31(11):1756-60. PubMed ID: 3324961
[TBL] [Abstract][Full Text] [Related]
6. Survey of amphotericin B susceptibility of Candida clinical isolates determined by Etest.
Chiu YS; Chang SC; Hsueh PR; Wang JL; Sun HY; Chen YC
J Microbiol Immunol Infect; 2006 Aug; 39(4):335-41. PubMed ID: 16926981
[TBL] [Abstract][Full Text] [Related]
7. [In vitro amphotericin B susceptibility of korean bloodstream yeast isolates assessed by the CLSI broth microdilution method, Etest, and Minimum fungicidal concentration test].
Park JY; Shin JH; Uh Y; Kim EC; Kee SJ; Kim SH; Shin MG; Suh SP; Ryang DW
Korean J Lab Med; 2008 Oct; 28(5):346-52. PubMed ID: 18971615
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal liposomal amphotericin B for treatment of endogenous candida endophthalmitis.
Bae JH; Lee SC
Jpn J Ophthalmol; 2015 Sep; 59(5):346-52. PubMed ID: 26215152
[TBL] [Abstract][Full Text] [Related]
9. [Short communication: In vitro activity of amphotericin B with fluconazole or voriconazole combinations against Candida albicans isolates].
Oz Y; Akşit F; Kiraz N; Kiremitçi A
Mikrobiyol Bul; 2008 Jan; 42(1):149-55. PubMed ID: 18444574
[TBL] [Abstract][Full Text] [Related]
10. Patterns of amphotericin B killing kinetics against seven Candida species.
Cantón E; Pemán J; Gobernado M; Viudes A; Espinel-Ingroff A
Antimicrob Agents Chemother; 2004 Jul; 48(7):2477-82. PubMed ID: 15215097
[TBL] [Abstract][Full Text] [Related]
11. In vitro evaluation of antifungal and cytotoxic activities as also the therapeutic safety of the oxidized form of amphotericin B.
Klimek K; Strubińska J; Czernel G; Ginalska G; Gagoś M
Chem Biol Interact; 2016 Aug; 256():47-54. PubMed ID: 27350166
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species.
Moore CB; Oakley KL; Denning DW
Clin Microbiol Infect; 2001 Jan; 7(1):11-6. PubMed ID: 11284937
[TBL] [Abstract][Full Text] [Related]
13. Antifungal Activity of Chitosan-Coated Poly(lactic-co-glycolic) Acid Nanoparticles Containing Amphotericin B.
Ludwig DB; de Camargo LEA; Khalil NM; Auler ME; Mainardes RM
Mycopathologia; 2018 Aug; 183(4):659-668. PubMed ID: 29497926
[TBL] [Abstract][Full Text] [Related]
14. Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans.
Louie A; Liu W; Miller DA; Sucke AC; Liu QF; Drusano GL; Mayers M; Miller MH
Antimicrob Agents Chemother; 1999 Dec; 43(12):2831-40. PubMed ID: 10582868
[TBL] [Abstract][Full Text] [Related]
15. Intrinsic in vitro susceptibility of primary clinical isolates of Aspergillus fumigatus, Aspergillus terreus, Aspergillus nidulans, Candida albicans and Candida lusitaniae against amphotericin B.
Singh J; Rimek D; Kappe R
Mycoses; 2006 Mar; 49(2):96-103. PubMed ID: 16466441
[TBL] [Abstract][Full Text] [Related]
16. [In vitro synergistic effect of moxifloxacin and amphotericin B combination against Candida strains].
Yalçin B; Kalkanci A; Gürelik F; Fidan I; Kustimur S; Ozdek S
Mikrobiyol Bul; 2010 Jan; 44(1):65-70. PubMed ID: 20455400
[TBL] [Abstract][Full Text] [Related]
17. Antifungal drug susceptibility of oral Candida albicans isolates may be associated with apoptotic responses to Amphotericin B.
Yang C; Gong W; Lu J; Zhu X; Qi Q
J Oral Pathol Med; 2010 Feb; 39(2):182-7. PubMed ID: 19656268
[TBL] [Abstract][Full Text] [Related]
18. Arabinogalactan protein from Arachis hypogaea: role as carrier in drug-formulations.
Parveen S; Gupta AD; Prasad R
Int J Pharm; 2007 Mar; 333(1-2):79-86. PubMed ID: 17084048
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of 2-cyclohexylidenhydrazo-4-phenyl-thiazole compared with those of amphotericin B and fluconazole against clinical isolates of Candida spp. and fluconazole-resistant Candida albicans.
De Logu A; Saddi M; Cardia MC; Borgna R; Sanna C; Saddi B; Maccioni E
J Antimicrob Chemother; 2005 May; 55(5):692-8. PubMed ID: 15772140
[TBL] [Abstract][Full Text] [Related]
20. Amphotericin B-copper(II) complex as a potential agent with higher antifungal activity against Candida albicans.
Chudzik B; Tracz IB; Czernel G; Fiołka MJ; Borsuk G; Gagoś M
Eur J Pharm Sci; 2013 Aug; 49(5):850-7. PubMed ID: 23791641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
